who owns the patent for retatrutide Eli Lilly is trying to classify Ret as a biological not a peptide. Thoughts? #elililly 🎥 Eli Lilly’s next generation

Patients should be advised to: Start with the lowest dose and increase slowly Eat smaller, more frequent meals Avoid high-fat foods Stay well-hydrated Safety monitoring should include vigilance for: Pancreatitis symptoms (severe persistent abdominal pain) discontinue immediately if suspected Gallbladder disease increased risk with rapid weight loss Hypoglycaemia particularly when combined with insulin or sulphonylureas Renal function deterioration especially with dehydration from gastrointestinal effects Diabetic retinopathy monitor in patients with pre-existing retinopathy, particularly with semaglutide Suspected adverse reactions should be reported via the MHRA Yellow Card scheme

Anticipated Developments Increased integration of telepharmacy services

doi: 10.1111/j.1476-5381.2009.00517.x

The injection form delivers medication directly into your subcutaneous tissue, bypassing stomach acid that would destroy oral GLP-1 compounds

The BPC-157 dosage calculator can help determine appropriate amounts for research protocols